Certara (NASDAQ:CERT) Posts Earnings Results

Certara (NASDAQ:CERT - Get Free Report) posted its earnings results on Monday. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04, Briefing.com reports. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same period in the previous year, the firm earned $0.10 EPS. The firm's revenue was up 9.7% compared to the same quarter last year.

Certara Stock Up 2.0 %

Shares of CERT traded up $0.24 during trading hours on Friday, reaching $12.11. 303,771 shares of the stock traded hands, compared to its average volume of 1,280,298. Certara has a 52 week low of $8.64 and a 52 week high of $17.76. The stock has a fifty day simple moving average of $11.67 and a 200 day simple moving average of $11.66. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -60.55, a PEG ratio of 9.29 and a beta of 1.57. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Analyst Ratings Changes

Several brokerages have recently weighed in on CERT. KeyCorp increased their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Robert W. Baird upped their target price on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $11.00 to $14.00 in a research note on Thursday. Finally, TD Cowen started coverage on Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.